A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Harmony Biosciences Holdings, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 81,200 shares of HRMY stock, worth $2.77 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
81,200
Previous 92,700 12.41%
Holding current value
$2.77 Million
Previous $2.8 Million 15.99%
% of portfolio
0.01%
Previous 0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$30.0 - $39.95 $345,000 - $459,425
-11,500 Reduced 12.41%
81,200 $3.24 Million
Q2 2024

Aug 14, 2024

SELL
$28.81 - $33.01 $1.71 Million - $1.96 Million
-59,500 Reduced 39.09%
92,700 $2.8 Million
Q1 2024

May 15, 2024

SELL
$29.93 - $35.06 $14,965 - $17,530
-500 Reduced 0.33%
152,200 $5.11 Million
Q4 2023

Feb 14, 2024

SELL
$19.2 - $33.78 $2.68 Million - $4.71 Million
-139,400 Reduced 47.72%
152,700 $4.93 Million
Q3 2023

Nov 14, 2023

SELL
$31.89 - $39.03 $3.53 Million - $4.32 Million
-110,700 Reduced 27.48%
292,100 $9.57 Million
Q2 2023

Aug 14, 2023

BUY
$30.5 - $37.4 $1.19 Million - $1.45 Million
38,900 Added 10.69%
402,800 $14.2 Million
Q1 2023

May 15, 2023

SELL
$30.8 - $53.92 $1.74 Million - $3.05 Million
-56,600 Reduced 13.46%
363,900 $11.9 Million
Q4 2022

Feb 14, 2023

BUY
$45.4 - $60.91 $4.93 Million - $6.61 Million
108,600 Added 34.82%
420,500 $23.2 Million
Q3 2022

Nov 14, 2022

BUY
$42.06 - $55.45 $3.15 Million - $4.15 Million
74,900 Added 31.6%
311,900 $13.8 Million
Q2 2022

Aug 15, 2022

BUY
$33.54 - $52.15 $2.35 Million - $3.66 Million
70,200 Added 42.09%
237,000 $11.6 Million
Q1 2022

May 16, 2022

BUY
$33.14 - $51.13 $5.53 Million - $8.53 Million
166,800 New
166,800 $8.12 Million

Others Institutions Holding HRMY

About Harmony Biosciences Holdings, Inc.


  • Ticker HRMY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,161,400
  • Market Cap $2.02B
  • Description
  • Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...
More about HRMY
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.